{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T12:55:58Z","timestamp":1770555358182,"version":"3.49.0"},"reference-count":36,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The association between radiological response and overall survival (OS) was retrospectively evaluated in patients treated with lenvatinib as a first-line systemic treatment for unresectable hepatocellular carcinoma. A total of 182 patients with Child\u2013Pugh class A liver function and an Eastern Cooperative Oncology Group performance status of zero or one were enrolled. Radiological evaluation was performed using Response Evaluation Criteria in Solid Tumors (RECIST) and modified Response Evaluation Criteria in Solid Tumors (mRECIST). Initial radiological evaluation confirmed significant stratification of OS by efficacy judgment with both RECIST and mRECIST, and that initial radiological response was an independent prognostic factor for OS on multivariate analysis. Furthermore, in patients with stable disease (SD) at initial evaluation, macrovascular invasion at the initial evaluation on RECIST and modified albumin\u2013bilirubin grade at initial evaluation on mRECIST were independent predictors of OS on multivariate analysis. In conclusion, if objective response is obtained at the initial evaluation, continuation of treatment appears desirable because prolonged OS can be expected; but, if SD is obtained at the initial evaluation, one should determine whether to continue or switch to the next treatment, with careful consideration of factors related to the tumor and hepatic reserve at the initial evaluation.<\/jats:p>","DOI":"10.3390\/cancers14020320","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T17:42:25Z","timestamp":1641836545000},"page":"320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-5203","authenticated-orcid":false,"given":"Kei","family":"Amioka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Johira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shirane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serami","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-0960","authenticated-orcid":false,"given":"Kensuke","family":"Naruto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwa","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-4946","authenticated-orcid":false,"given":"Shinsuke","family":"Uchikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4960","authenticated-orcid":false,"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-945X","authenticated-orcid":false,"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"},{"name":"Department of Clinical Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0745-991X","authenticated-orcid":false,"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nami","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima 730-8619, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Takaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima 730-8619, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima 730-8619, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima 731-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima 731-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Kouno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Moriya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Hiroshima 737-0193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Naeshiro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Higashihiroshima Medical Center, Hiroshima 739-0041, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima 738-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Hyogo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima 738-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Aisaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima 738-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Azakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Memorial Hospital, Hiroshima 730-0802, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Memorial Hospital, Hiroshima 730-0802, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-2156","authenticated-orcid":false,"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/cncr.21832","article-title":"Combination therapy of intra-arterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion","volume":"106","author":"Obi","year":"2006","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cncr.20892","article-title":"Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases","volume":"103","author":"Tateishi","year":"2005","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0002-9610(99)80227-X","article-title":"Criteria for safe hepatic resection","volume":"169","author":"Miyagawa","year":"1995","journal-title":"Am. J. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-007-2099-8","article-title":"Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil\/interferon combination therapy in patients with advanced hepatocellular carcinoma","volume":"42","author":"Uka","year":"2007","journal-title":"J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S1470-2045(19)30165-2","article-title":"Ramucirumab in advanced hepatocellular carcinoma in REACH-2: The true value of alpha-fetoprotein","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rizzo, A., Dadduzio, V., Ricci, A.D., Massari, F., Di Federico, A., Gadaleta-Caldarola, G., and Brandi, G. (2021). Lenvatinib plus pembrolizumab: The next frontier for the treatment of hepatocellular carcinoma?. Expert Opin. Investig. Drugs, 1\u20138.","DOI":"10.1080\/13543784.2021.1948532"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"733530","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral status and efficacy of immunotherapy in hepatocellular carcinoma: A systematic review with meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000488778","article-title":"Validation of modified ALBI grade for more detailed assessing hepatic function in hepatocellular carcinoma patients: A multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kirino, S., Tsuchiya, K., Kurosaki, M., Kaneko, S., Inada, K., Yamashita, K., Osawa, L., Hayakawa, Y., Sekiguchi, S., and Okada, M. (2020). Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231828"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Saeki, I., Yamasaki, T., Yamashita, S., Hanazono, T., Urata, Y., Furutani, T., Yokoyama, Y., Oishi, T., Maeda, M., and Kimura, T. (2020). Early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment. Cancers, 12.","DOI":"10.3390\/cancers12040779"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fuchigami, A., Imai, Y., Uchida, Y., Uchiya, H., Fujii, Y., Nakazawa, M., Ando, S., Sugawara, K., Nakayama, N., and Tomiya, T. (2020). Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231427"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1002\/cam4.2241","article-title":"Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions\u2014Multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.esmoop.2020.100020","article-title":"Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma","volume":"6","author":"Nakano","year":"2021","journal-title":"ESMO Open"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shomura, M., Okabe, H., Sato, E., Fukai, K., Shiraishi, K., Hirose, S., Tsuruya, K., Arase, Y., Anzai, K., and Kagawa, T. (2020). Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy. Cancers, 12.","DOI":"10.3390\/cancers12113078"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/liv.13359","article-title":"mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib","volume":"37","author":"Meyer","year":"2017","journal-title":"Liver Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Vincenzi, B., Di Maio, M., Silletta, M., D\u2019Onofrio, L., Spoto, C., Piccirillo, M.C., Daniele, G., Comito, F., Maci, E., and Bronte, G. (2015). Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133488"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/hepr.13416","article-title":"Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib","volume":"50","author":"Kaneko","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000497460","article-title":"Objective response by mRECIST is an independent prognostic factor of overall survival in systemic therapy for hepatocellular carcinoma","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000513355","article-title":"What can be done to solve the unmet clinical need of hepatocellular carcinoma patients following lenvatinib failure","volume":"10","author":"Hiraoka","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/hepr.13452","article-title":"Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma","volume":"50","author":"Kuzuya","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000512781","article-title":"Clinical outcomes with multikinase Inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational multicenter retrospective study","volume":"10","author":"Yoo","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10637-019-00801-8","article-title":"Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: A multicenter retrospective study in Japan","volume":"38","author":"Ogasawara","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1159\/000509387","article-title":"Analysis of post-progression survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib","volume":"98","author":"Ando","year":"2020","journal-title":"Oncology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000504624","article-title":"Effects of subsequent systemic anticancer medication following first-line lenvatinib: A post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma","volume":"9","author":"Alsina","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_36","unstructured":"(2021, October 21). Prospective Observational Study of Systemic Therapy for Unresectable HCC in Japan: Real World Data of Systemic Therapy for HCC; UMIN ID 000040488. Available online: https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000046213."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/2\/320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:27:10Z","timestamp":1760362030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/2\/320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["cancers14020320"],"URL":"https:\/\/doi.org\/10.3390\/cancers14020320","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]}}}